MoonLake Immunotherapeutics Closes $100M Public Offering

Ticker: MLTX · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1821586

Moonlake Immunotherapeutics 8-K Filing Summary
FieldDetail
CompanyMoonlake Immunotherapeutics (MLTX)
Form Type8-K
Filed DateMar 11, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentbullish

Sentiment: bullish

Topics: public-offering, financing, healthcare

TL;DR

MoonLake closed its $100M public offering at $10/share, raising capital for its pipeline.

AI Summary

On March 10, 2024, MoonLake Immunotherapeutics announced the closing of its previously announced underwritten public offering. The company successfully raised approximately $100 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. This offering involved the sale of 10,000,000 ordinary shares at a public offering price of $10.00 per share.

Why It Matters

The successful completion of this $100 million offering provides MoonLake Immunotherapeutics with significant capital to advance its clinical programs and further its development in the immunotherapy space.

Risk Assessment

Risk Level: medium — While the capital raise is positive, the company is still in the development phase, and the success of its pipeline drugs carries inherent clinical and regulatory risks.

Key Numbers

  • $100.0M — Gross Proceeds (Raised from public offering)
  • 10.0M — Shares Sold (In the public offering)
  • $10.00 — Price Per Share (Public offering price)

Key Players & Entities

  • MoonLake Immunotherapeutics (company) — Registrant
  • March 10, 2024 (date) — Closing date of public offering
  • $100 million (dollar_amount) — Gross proceeds from public offering
  • 10,000,000 (dollar_amount) — Number of ordinary shares sold
  • $10.00 (dollar_amount) — Public offering price per share

FAQ

What was the total amount of gross proceeds raised by MoonLake Immunotherapeutics in its recent public offering?

MoonLake Immunotherapeutics raised approximately $100 million in gross proceeds from its underwritten public offering.

On what date did MoonLake Immunotherapeutics announce the closing of its public offering?

The company announced the closing of its public offering on March 10, 2024.

How many ordinary shares did MoonLake Immunotherapeutics sell in the public offering?

MoonLake Immunotherapeutics sold 10,000,000 ordinary shares in the public offering.

What was the public offering price per share for MoonLake Immunotherapeutics' ordinary shares?

The public offering price per share was $10.00.

What is the principal executive office address for MoonLake Immunotherapeutics?

The principal executive offices are located at Dorfstrasse 29, 6300 Zug, Switzerland.

Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-11 08:01:23

Key Financial Figures

  • $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On March 10, 2024, MoonLake Immunotherapeutics (the "Company") issued a press release titled "MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

01. Other Events

Item 8.01. Other Events. On March 10, 2024, MoonLake Immunotherapeutics (the "Company") made available the presentation used in the Company's March 10, 2024 R&D Day on the Company's website. A copy of the presentation is filed herewith as Exhibit 99.2 and incorporated herein by reference

01. Financial

Item 9.01. Financial (d) Exhibits . The following exhibit is being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated March 10, 2024 99.2 Slide Presentation, dated March 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOONLAKE IMMUNOTHERAPEUTICS Date: March 11, 2024 By: /s/ Matthias Bodenstedt Name: Matthias Bodenstedt Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.